Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$103.14 USD

103.14
5,076,184

+0.18 (0.17%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $103.11 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.

Zacks Equity Research

HAE or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

Zacks Equity Research

Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.

Zacks Equity Research

DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its second-quarter performance.

Zacks Equity Research

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.

Zacks Equity Research

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Boston Scientific (BSX)

by Zacks Equity Research

Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Merit Medical (MMSI) Q2 Earnings & Revenues Beat, '24 View Up

by Zacks Equity Research

Merit Medical's (MMSI) second-quarter results reflect growth in earnings and revenues. Operating margin expands.

Zacks Equity Research

BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.

Zacks Equity Research

Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts

by Zacks Equity Research

Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.

Zacks Equity Research

QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

by Zacks Equity Research

QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.

Urmimala Biswas headshot

Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?

by Urmimala Biswas

Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Boston Scientific (BSX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Boston Scientific (BSX) stock based on the movements in the options market lately.

Zacks Equity Research

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales

by Zacks Equity Research

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

Zacks Equity Research

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Zacks Equity Research

Boston Scientific (BSX) Rides on Global Growth, Buyouts

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Zacks Equity Research

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

Zacks Equity Research

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

by Zacks Equity Research

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.

Zacks Equity Research

Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.

Zacks Equity Research

Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.

Zacks Equity Research

Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

by Zacks Equity Research

Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.

Zacks Equity Research

Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.